Vyome Holdings Inc (HIND)

Currency in USD
2.210
-0.050(-2.21%)
Closed·
2.276+0.066(+2.96%)
·
HIND is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
2.1582.270
52 wk Range
1.75056.380
Key Statistics
Prev. Close
2.26
Open
2.22
Day's Range
2.158-2.27
52 wk Range
1.75-56.38
Volume
36.7K
Average Volume (3m)
842.26K
1-Year Change
-94.2692%
Book Value / Share
0.43
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
HIND Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
15.000
Upside
+578.73%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Vyome Holdings Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments. The company’s lead product candidate VT-1953, a dual DNA Gyrase/Topoisomerase inhibitor and immunomodulator in a topical gel formulation that is in phase 2 clinical stage for the treatment of bacterial conjunctivitis. It also develops VT-1908, a topical eye drop is an inosine 5'-monophosphate dehydrogenase enzyme inhibitor to treat immunoinflammatory conditions of the eye; and VB-1953, which is in phase 2 clinical stage for the treatment of inflammatory acne. In addition, the company develops antifungal products using the molecular replacement therapy (MRT) platform. It has a collaboration and license agreement with Sun Pharma Laboratories Limited to develop and commercialize next-generation antifungal products. The company is based in Cambridge, Massachusetts.

Vyome Holdings Inc Earnings Call Summary for Q3/2025

  • Vyome Holdings reported a Q3 2025 net loss of $9.2 million due to merger-related charges, with stock declining 4.56% to $4.40 in premarket trading.
  • The company extended its cash runway through 2026 despite financial challenges, reporting $5.7 million in cash and equivalents with 5,556,295 outstanding shares.
  • Positive interim Phase 2 results for lead program VT1953 were announced, with FDA interactions planned for H1 2026 as part of pipeline development.
  • Leadership was strengthened with a new CTO and Senior VP of Clinical Development, while the company completed its NASDAQ listing with 100% common stock structure.
  • Vyome is pursuing an AI-focused healthcare initiative through acquisitions, leveraging its strategic position bridging U.S. and India innovation corridors.
Last Updated: 2025-11-20, 10:52 a/m
Read Full Transcript

Compare HIND to Peers and Sector

Metrics to compare
HIND
Peers
Sector
Relationship
P/E Ratio
−1.5x−3.6x−0.5x
PEG Ratio
-−0.160.00
Price/Book
6.4x3.1x2.6x
Price / LTM Sales
48.5x3.0x3.2x
Upside (Analyst Target)
-44.6%47.4%
Fair Value Upside
Unlock16.3%7.7%Unlock

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 15.000
(+578.73% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
Mar 18, 2026
EPS / Forecast
-0.21 / -0.13
Revenue / Forecast
36.55K / --
EPS Revisions
Last 90 days

HIND Income Statement

People Also Watch

7.1200
JTAI
-7.41%
0.713
EONR
-6.18%
2.190
HCTI
-2.67%
0.5875
ONCO
-11.84%

FAQ

What Is the Vyome Holdings (HIND) Stock Price Today?

The Vyome Holdings stock price today is 2.210 USD.

What Stock Exchange Does Vyome Holdings Trade On?

Vyome Holdings is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Vyome Holdings?

The stock symbol for Vyome Holdings is "HIND."

What Is the Vyome Holdings Market Cap?

As of today, Vyome Holdings market cap is 15.580M USD.

What Is Vyome Holdings's Earnings Per Share (TTM)?

The Vyome Holdings EPS (TTM) is -4.748.

From a Technical Analysis Perspective, Is HIND a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Vyome Holdings Stock Split?

Vyome Holdings has split 11 times.

How Many Employees Does Vyome Holdings Have?

Vyome Holdings has 14 employees.

What is the current trading status of Vyome Holdings (HIND)?

As of Apr 25, 2026, Vyome Holdings (HIND) is trading at a price of 2.210 USD, with a previous close of 2.260 USD. The stock has fluctuated within a day range of 2.158 USD to 2.270 USD, while its 52-week range spans from 1.750 USD to 56.380 USD.

What Is Vyome Holdings (HIND) Price Target According to Analysts?

The average 12-month price target for Vyome Holdings is 15.000 USD, with a high estimate of 15 USD and a low estimate of 15 USD. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +578.73% Upside potential.

What Is the HIND Premarket Price?

HIND's last pre-market stock price is 2.323 USD. The pre-market share volume is 840.000, and the stock has decreased by 0.063, or 2.790%.

What Is the HIND After Hours Price?

HIND's last after hours stock price is 2.276 USD, the stock has decreased by 0.066, or 2.960%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.